S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:CTSO

Cytosorbents Stock Forecast, Price & News

$7.96
-0.15 (-1.85 %)
(As of 10/29/2020 04:30 PM ET)
Add
Compare
Today's Range
$7.83
Now: $7.96
$8.16
50-Day Range
$7.37
MA: $8.17
$8.87
52-Week Range
$3.49
Now: $7.96
$11.74
Volume275,527 shs
Average Volume604,440 shs
Market Capitalization$343.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.48
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol for treatment of severe hyperkalemia with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Read More
Cytosorbents logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885
Employees156

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.95 million
Book Value$0.11 per share

Profitability

Net Income$-19,270,000.00

Miscellaneous

Market Cap$343.54 million
Next Earnings Date11/4/2020 (Confirmed)
OptionableOptionable
$7.96
-0.15 (-1.85 %)
(As of 10/29/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

How has Cytosorbents' stock price been impacted by Coronavirus (COVID-19)?

Cytosorbents' stock was trading at $4.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CTSO shares have increased by 66.9% and is now trading at $7.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cytosorbents?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cytosorbents
.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cytosorbents
.

How can I listen to Cytosorbents' earnings call?

Cytosorbents will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) posted its earnings results on Tuesday, August, 4th. The medical research company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The medical research company earned $9.80 million during the quarter, compared to the consensus estimate of $9.79 million. Cytosorbents had a negative net margin of 53.56% and a negative return on equity of 122.99%.
View Cytosorbents' earnings history
.

What price target have analysts set for CTSO?

6 equities research analysts have issued 12 month price targets for Cytosorbents' shares. Their forecasts range from $14.00 to $17.00. On average, they anticipate Cytosorbents' stock price to reach $15.17 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price.
View analysts' price targets for Cytosorbents
.

Who are some of Cytosorbents' key competitors?

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Opko Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the following people:
  • Dr. Phillip P. Chan, CEO, Pres & Director (Age 50, Pay $549.64k)
  • Mr. Vincent J. Capponi M.S., MS, Pres & COO (Age 62, Pay $420.8k)
  • Ms. Kathleen P. Bloch CPA, M.B.A., MBA, CPA, CFO & Sec. (Age 65, Pay $373.9k)
  • Dr. Christian Steiner M.D., Sr. VP of Sales & Marketing
  • Mr. Christopher Cramer, VP of Bus. Devel.
  • Dr. Efthymios N. Deliargyris M.D., FACC, FESC, FSCAI, Chief Medical Officer (Age 52)
  • Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 81)

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a number of institutional and retail investors. Top institutional investors include Skylands Capital LLC (3.29%), Assenagon Asset Management S.A. (0.18%), Bradley Foster & Sargent Inc. CT (0.09%) and Cypress Capital Group (0.02%). Company insiders that own Cytosorbents stock include Kathleen P Bloch, Phillip P Chan and Vincent Capponi.
View institutional ownership trends for Cytosorbents
.

Which institutional investors are selling Cytosorbents stock?

CTSO stock was sold by a variety of institutional investors in the last quarter, including Cypress Capital Group.
View insider buying and selling activity for Cytosorbents
.

Which institutional investors are buying Cytosorbents stock?

CTSO stock was acquired by a variety of institutional investors in the last quarter, including Skylands Capital LLC, Assenagon Asset Management S.A., and Bradley Foster & Sargent Inc. CT. Company insiders that have bought Cytosorbents stock in the last two years include Kathleen P Bloch, and Phillip P Chan.
View insider buying and selling activity for Cytosorbents
.

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $7.96.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $343.54 million and generates $24.95 million in revenue each year. The medical research company earns $-19,270,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. Cytosorbents employs 156 workers across the globe.

What is Cytosorbents' official website?

The official website for Cytosorbents is www.cytosorbents.com.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.